125 patents currently held
20 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Jun 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
10
Ending by 2030
Jun 2028
Next term end
88
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2034 · High confidence
Also notable
Ends Aug 2035 · High confidence
Also notable
Ends Dec 2029 · Low confidence
Also notable
Ends Apr 2036 · High confidence
Also notable
Ends Apr 2036 · High confidence
Also notable
Ends Aug 2032 · High confidence
Also notable
Ends Sep 2034 · High confidence
Also notable
Ends Oct 2034 · High confidence
Fusion Proteins That Facilitate Cancer Cell Destruction
US 9,873,747
The most cited patent in this portfolio, cited by 49 later US patents, top 5% of utility patents granted in 2018 in our data. Protection runs to 2034.
Agonist Fusion Protein for CD40 and OX40 and Methods of Stimulating the Immune System
US 10,533,054
Cited by 31 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2035.
Design and Development of Masked Therapeutic Antibodies to Limit Off-Target Effects
US 10,357,571
Cited by 22 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Methods and Compositions for Treating Cancers and Enhancing Therapeutic Immunity by Selectively Reducing Immunomodulatory M2 Monocytes
US 10,206,942
Cited by 17 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2036.
Methods and Compositions for Treating Cancers Using Antisense
US 11,801,259
Cited by 4 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Composition and Method for Muscle Repair and Regeneration
US 9,789,074
Cited by 25 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Human Mirnas for Use in Diagnosis, Prognosis, and Therapy of Human Conditions and Diseases
US 11,293,064
Cited by 8 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2034.
4-((2-Hydroxy-3-Methoxybenzyl)AMINO)BENZENESULFONAMIDE Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase
US 10,266,488
Granted 2019. Computed term ends 2034.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 21, 2026The maintenance fee for Composition and Method for Muscle Repair and Regeneration (US 10,292,954) comes due Nov 21, 2026. Unpaid by May 21, 2027, it lapses early.
- 2 fees due Dec 6 to 16, 2026 · next Dec 6
- 3 fees due Jan 23 to 30, 2027 · next Jan 23
- 1 fee due Feb 1, 2027The maintenance fee for Systems-Level Analysis of 32 Tcga Cancers Reveals Disease-Dependent Trna Fragmentation Patterns and Very Selective Associations with Messenger RNAs and Repeat Elements (US 11,715,549) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 5 fees due Mar 12 to 26, 2027 · next Mar 12
- 2 fees due Apr 13 to 30, 2027 · next Apr 13
- 2 fees due May 26 to 28, 2027 · next May 26
- 4 fees due Jun 3 to 30, 2027 · next Jun 3
- 3 fees due Jul 14 to 28, 2027 · next Jul 14
- 3 fees due Aug 2 to 27, 2027 · next Aug 2
- 2 fees due Sep 17 to 30, 2027 · next Sep 17
- 3 fees due Oct 14 to 30, 2027 · next Oct 14
- 2 fees due Nov 7, 2027
Recent changes
- 3 of the patents on this record were granted since Aug 23, 2026
- 1 term has ended since Aug 23, 2026
- Sep 2 US 8,822,665 Neuron Generation, Regeneration and Protection · lapsed on the fee record
What they patent
The largest of its 88 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,574,206 | Engineered Biomass with Increased Oil Production In force · Low confidence | In force | Low confidence | |
| US 8,383,601 | Tissue Specific Gene Therapy Treatment In force · High confidence | In force | High confidence | |
| US 8,895,702 | Design and Development of Masked Therapeutic Antibodies to Limit Off-Target Effects; Application to Anti-Egfr Antibodies held by City of Hope and Thomas Jefferson University In force · Medium confidence | In force | Medium confidence | |
| US 10,357,571 | Design and Development of Masked Therapeutic Antibodies to Limit Off-Target Effects In force · Low confidence | In force | Low confidence | |
| US 11,186,642 | Development of Masked Therapeutic Antibodies to Limit Off-Target Effects: Application to Anti-Egfr Antibodies held by City of Hope and Thomas Jefferson University In force · Low confidence | In force | Low confidence | |
| US 8,999,707 | Method of Making Hybrid Cells That Express Useful Antibodies In force · High confidence | In force | High confidence | |
| US 8,557,575 | Fusion Partner Cell Line for Preparation of Hybrid Cells Expressing Human Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 9,249,194 | Neuron Generation, Regeneration and Protection held by Institut Pasteur and Thomas Jefferson University In force · High confidence | In force | High confidence | |
| US 11,311,622 | Design and Development of Masked Therapeutic Antibodies to Limit Off-Target Effects In force · Medium confidence | In force | Medium confidence | |
| US 8,282,939 | Attenuated Live Triple G Protein Recombinant Rabies Virus Vaccine for Pre- and Post-Exposure Prophylaxis of Rabies In force · High confidence | In force | High confidence |
Also on record, not counted in the 125: 20 patents in force now held by others · 78 patents ended · 100 applications pending · 196 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.